Search hospitals
>
Illinois
>
Urbana
The Carle Foundation Hospital
Claim this profile
Urbana, Illinois 61801
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
312 reported clinical trials
21 medical researchers
Summary
The Carle Foundation Hospital is a medical facility located in Urbana, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. The Carle Foundation Hospital is involved with conducting 312 clinical trials across 480 conditions. There are 21 research doctors associated with this hospital, such as Suparna Mantha, Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, and Kendrith Rowland, MD.
Area of expertise
Lung Cancer
The Carle Foundation Hospital has run 41 trials for Lung Cancer. Some of their research focus areas include:
Breast Cancer
The Carle Foundation Hospital has run 38 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Suparna Mantha
Carle Cancer Center
6 years of reported clinical research
Vamsi K. Vasireddy
Carle Cancer Center
3 years of reported clinical research
Maria T. Grosse-Perdekamp
Carle Cancer Center
3 years of reported clinical research
Kendrith Rowland, MD
Carle Cancer Center
8 years of reported clinical research
Clinical Trials running at The Carle Foundation Hospital
Lung Cancer
Kidney Cancer
Bladder Cancer
Bladder Carcinoma
Prostate Cancer
Melanoma
Cutaneous Melanoma
Non-Small Cell Lung Cancer
Multiple Myeloma
Testicular cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting
2 awards
Phase 3
15 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at The Carle Foundation Hospital?
The Carle Foundation Hospital is a medical facility located in Urbana, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. The Carle Foundation Hospital is involved with conducting 312 clinical trials across 480 conditions. There are 21 research doctors associated with this hospital, such as Suparna Mantha, Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, and Kendrith Rowland, MD.
Where is The Carle Foundation Hospital located?
Carle Foundation Hospital is located at 611 W Park St, Urbana, Illinois, near the intersection of W Park St and N Lincoln Ave. For detailed maps and parking information, please consult the Carle Campus Map.
Who should I call to ask about financial aid or insurance network?
The Carle Foundation Hospital offers financial assistance and insurance support. Patients can contact the Patient Financial Services department for inquiries at (888) 71-CARLE, available Monday to Friday, 8 a.m. to 5 p.m. Financial assistance applications can be downloaded from the Carle Health website or picked up at any Carle location, supporting documents required include certification of household's gross annual income, size, and residency.
What insurance does The Carle Foundation Hospital accept?
The Carle Foundation Hospital accepts a variety of Medicare Advantage plans from Health Alliance, including: - Health Alliance Medicare HMO 20 Rx (HMO) - Health Alliance Medicare POS 10 Rx (HMO-POS) - Health Alliance Medicare POS Choice Rx (HMO-POS) - Health Alliance Medicare HMO Basic (HMO) - Health Alliance Medicare POS Basic Rx (HMO-POS) - Health Alliance Medicare POS Enrich Rx (HMO-POS) These plans vary in monthly premiums, deductibles, out-of-pocket maximums, and prescription drug coverage. Carle Health plans provide both in-network and out-of-network coverage, with lower costs for in-network providers. Patients should verify their insurance coverage to understand their benefits.
What awards or recognition has The Carle Foundation Hospital received?
The Carle Foundation Hospital, located in Urbana, Illinois, is renowned for its innovative healthcare research via the Stephens Family Clinical Research Institute, focusing on disease prevention, detection, and treatment. It has been named one of America's 50 Best Hospitalsâ„¢ for the 7th consecutive year by Healthgrades, ranking it in the top one percent nationwide for clinical care and patient outcomes.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.